size-exclusion HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-12. Numbers and descriptions here follow the published literature rather than marketing material.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
=== EC 1.7.1 With NAD+ or NADP+ as acceptor === EC 1.7.1.1: nitrate reductase (NADH) EC 1.7.1.2: nitrate reductase (NAD(P)H) EC 1.7.1.3: nitrate reductase (NADPH) EC 1.7.1.4: nitrite reductase (NAD(P)H) EC 1.7.1.5: hyponitrite reductase EC 1.7.1.6: azobenzene reductase EC 1.7.1.7: GMP reductase EC 1.7.1.8: deleted EC 1.7.1.9: nitroquinoline-N-oxide reductase EC 1.7.1.10: hydroxylamine reductase (NADH) EC 1.7.1.11: 4-(dimethylamino)phenylazoxybenzene reductase EC 1.7.1.12: N-hydroxy-2-acetamidofluorene reductase EC 1.7.1.13: preQ1 synthase EC 1.7.1.14: nitric oxide reductase (NAD(P), nitrous oxide-forming) EC 1.7.1.15: nitrite reductase (NADH) EC 1.7.1.16: nitrobenzene nitroreductase EC 1.7.1.17: FMN-dependent NADH-azoreductase
== Adverse reactions == The main toxicities described with intravenous treatment are nephrotoxicity (damage to the kidneys) and neurotoxicity (damage to the nerves), but this may reflect the very high doses given, which are much higher than the doses currently recommended by any manufacturer and for which no adjustment was made for pre-existing renal disease. Neuro- and nephrotoxic effects appear to be transient and subside on discontinuation of therapy or reduction in dose. At a dose of 160 mg colistimethate IV every eight hours, very little nephrotoxicity is seen. Indeed, colistin appears to have less toxicity than the aminoglycosides that subsequently replaced it, and it has been used for extended periods up to six months with no ill effects. Colistin-induced nephrotoxicity is particularly likely in patients with hypoalbuminemia. The main toxicity described with aerosolised treatment is bronchospasm, which can be treated or prevented with the use of β2-adrenergic receptor agonists such as salbutamol or following a desensitisation protocol.
== History == Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome (SARS) and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell. In 2012, the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016. In June 2017, Sarepta Therapeutics appointed former Allergan executive Doug Ingram as its new CEO to replace Edward Kaye who had announced plans to step down earlier that year.
Sources: en.wikipedia.org
=== Dentures throughout the ages === The use of "false teeth" has prevailed throughout the course of history. Archaeological evidence dating back to 1500 B.C. was found in Egypt. The Egyptians would use real teeth threaded with a gold wire to create a false set of teeth. In northern Italy 700 B.C., the Etruscans made dentures out of animal teeth. Hence the world of dental prosthodontics began to take shape. Despite being made of low quality material and having short life spans, dentures were relatively popular. The first complete set of dentures is attributed to 16th century Japan. They were known as the Japanese box and are quite similar in shape to modern day dentures.
==== United Kingdom ==== Phenazepam is a class C drug in the UK. The UK Home Office banned importation of phenazepam on Friday 22 July 2011 while it drafted legislation, released in January 2012 to become law at the end of March 2012. The bill was quashed following advice from the ACMD as it included two non-abusable steroids. There was a new discussion about its fate on April 23, 2012, where it was decided that the bill would be rewritten and phenazepam would still be banned. It was eventually banned on June 13, 2012 as a class C, schedule II drug.
Cmin is a term used in pharmacokinetics for the minimum blood plasma concentration reached by a drug during a dosing interval, which is the time interval between administration of two doses. This definition is slightly different from Ctrough, the concentration immediately prior to administration of the next dose. Cmin is the opposite of Cmax, the maximum concentration that the drug reaches. Cmin must be above certain thresholds, such as the minimum inhibitory concentration (MIC), to achieve a therapeutic effect. In most cases Cmin is directly measurable. At steady state the minimum plasma concentration can also be calculated using the following equation:
== Habitat == When first discovered, Roseiflexus castenholzii was isolated from the lowest layer of a three layered bacterial mat; the top two layers contained cyanobacteria and Chloroflexus spp. These mats were found in multiple Japanese hot springs ranging in temperature from 45.5 °C to 68.5 °C and with a neutral to alkaline pH range. This bacterium is able to grow photoheterotrophically under anaerobic light conditions and chemoheterotrophically under aerobic dark conditions. Optimal growth conditions for this organism are 50 °C and pH 7.5–8.0. The first isolated type strain was HLO8T (= DSM 13941T = JCM 11240T).
Sources: en.wikipedia.org
The doublet at 1.31 ppm is typically quantified as the quartet may be suppressed through water saturation or obscured by residual water. In healthy subjects lactate is not visible, for its concentration is lower than the detection limit of MRS; however, presence of this peak indicates glycolysis has been initiated in an oxygen-deficient environment. Several causes of this include ischemia, hypoxia, mitochondrial disorders, and some types of tumors. Myo-inositol: with its major peak at 3.56 ppm, an increase in Myo-inositol has been seen to be disrupted in patients with Alzheimer's, dementia, and HIV patients. Glutamate and glutamine: these amino acids are marked by a series of resonance peaks between 2.2 and 2.4 ppm. Hyperammonemia, hepatic encephalopathy are two major conditions that result in elevated levels of glutamine and glutamate. MRS, used in conjunction with MRI or some other imaging technique, can be used to detect changes in the concentrations of these metabolites, or significantly abnormal concentrations of these metabolites. GABA can be detected primarily from its peaks at approximately 3.0 ppm, however because creatine has a strong singlet at 3.0 ppm with approximately 20x the amplitude a technique which exploits J-coupling must be used to accurately quantify GABA. The most common techniques for this are J-difference editing (MEGA), or J-resolved (as used in JPRESS) Glutathione can also be detected from its peak at peak at 3.0 ppm, however similar to GABA it also must use a method which exploits J-coupling to remove the overlaying creatine signal.
Yavne was established in October 1948 as a transit camp for Jews from Arab countries, Iran and Europe. The first neighbourhood was established in early 1949. In the early years, the inhabitants were shopkeepers, farmers and construction workers. In 1953, the population was 1,600. In the 1960s, several enterprises moved from Tel Aviv to Yavne, establishing leather, textile, and metallurgy industries. By 1970, the population had grown to 10,100. Other Israeli villages were founded on Yibna land were Kfar HaNagid and Beit Gamliel in 1949, Ben Zakai in 1950, Kfar Aviv (originally: "Kfar HaYeor") in 1951, Tzofiyya in 1955. According to Walid Khalidi, a railroad crosses the village. The old mosque and minaret, together with a shrine can still be seen, and some of the old houses are inhabited by Jewish and Arab families. The 1980 edition of a guidebook published in Jerusalem describes Yavne as home to Israel's first atomic reactor, an image of which appeared on a 0.50 Shekel stamp. When Mayor Meir Sheetrit assumed office in 1974, the city became a low-density suburban satellite of Tel Aviv with new construction targeting middle-class families. Yavne achieved city status in 1986. By the mid-1990s, the population had risen to 25,600.
=== Mating === Males attract females by singing via stridulation. An interested female will respond singing a similar-sounding song. The male will respond to the female by singing again. This can continue until copulation or the female becomes disinterested. Although a female response to male song does not guarantee mating it does increase the likelihood of copulation. Upon contact the male will produce a soft song and mount the female.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.